RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - STUDIO DEI MECCANISMI MOLECOLARI DI ATTIVITA'/RESISTENZA DI SOSTANZE ANTIMICROBICHE
• 2 - Definizione del rapporto tra la somministrazione di terapia antibiotica e lo sviluppo di infezioni causate da germi antibiotico-resistenti. Sviluppo di linee guida e modelli di prevenzione.
• 3 - La resistenza agli antiparassitari in Artropodi di interesse agrario: studi su diffusione, meccanismi e basi genetico-molecolari
• 4 - Geni di resistenza nei microrganismi patogeni Gram-positivi e Gram-negativi: caratterizzazione molecolare, funzionale e loro trasferimento orizzontale.
• 5 - Problemi emergenti di antibiotico-resistenza e virulenza in batteri patogeni Gram-positivi e Gram-negativi.
• 6 - Meccanismi molecolari ed effetti biologici della resistenza agli antibiotici in cocchi e bacilli Gram-positivi
• 7 - Studio delle basi molecolari per un'ottimizzazione della terapia mirata con inibitori delle tirosin-kinasi: il caso della leucemia mieloide cronica e di altre neoplasie ematologiche
• 8 - Stress percepito, dimensioni psicopatologiche, personologiche e correlati immunologici in pazienti Helicobacter pylori positivi, resistenti alla farmacoterapia eradicante vs. responders. Studio di follow-up.
• 9 - Antibiotico-resistenza, virulenza e fitness in patogeni Gram-positivi e Gram-negativi.
• 10 - PATOGENESI E TERAPIA DELLE MALATTIE DA INFEZIONE

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • MICROBIOLOGIA E MICROBIOLOGIA CLINICA
  • MALATTIE INFETTIVE

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
• PHYSICS
  • MEASURING (counting G06M); TESTING
    • INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (separating components of materials in general B01D, B01J, B03, B07; apparatus fully provided for in a single other subclass, see the relevant subclass e.g. B01L; measuring or testing processes other than immunoassay, involving enzymes or micro-organisms C12M, C12Q; investigation of foundation soil in situ E02D1/00; sensing humidity changes for compensating measurements of other variables or for compensating readings of instruments for variations in humidity, see G01D or the relevant subclass for the variable measured; testing or determining the properties of structures G01M; measuring or investigating electric or magnetic properties of materials G01R; systems or methods in general, using reception or emission of radiowaves or other waves and based on propagation effects, e.g. Doppler effect, propagation time, direction of propagation, G01S; determining sensivity, graininess, or density of photographic materials G03C5/02; testing component parts of nuclear reactors G21C17/00; [N: controlling or regulating non-electric variables G05D; measuring degree of ionisation of ionised gases, i.e. plasma H05H1/00A; testing electrographic developer properties G03G15/08H6])

Classificazione geografica

• Regione: Lombardia

Bibliografia

1. Wensing AMJ, van de Vijver DAMC, Asjo B et al. Prevalence of trasmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implication; 2003 10-14 June; Los Cabos, Mexico. Abs 117.
2. Blower SM. Transmission of zidovudine resistant strains of HIV-1: the first wave. AIDS 2001; 15: 2317-8
3. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal Medicine 2002; 347: 385-94.
4. Yerly S,Vora S, Rizzardi P, et al Acute HIV infection: impact on the spread of HIV and transmission of drug resistance AIDS 2001;15:2287-92.
5. Violin M, Velleca R, Cozzi-Lepri A et al. Prevalence of HIV-1 Primary Drug Resistance in Seroconverters of the ICoNA Cohort Over the Period 1996-2001. Journal Acquired Immune Deficiency Syndromes. 2004 Jun 1;36:761-764.
6. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
7. Palella FJ Jr, Delaney KM et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 ;338:853-60
8. Finzi D, Hermankova M et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-300.
9. Schambelan M, Benson CA, Carr A et al Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002 ;31:257-75
10. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. Acquir Immune Defic Syndr. 2002 ;31 Suppl 3:S98-102.
11. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247-277.
12. Castiglione F, Poccia F et al. Mutation, fitness, viral diversity, and predictive markers of disease progression in a computational model of HIV type 1 infection. AIDS Res Hum Retroviruses. 2004; 20:1314-23.
13. Antinori A, Liuzzi G et al. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. AIDS. 2001 Nov 23;15:2325-7.
14. Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis 2003; 36:373-377.
15. Hernando V, Palmer P, Sauvageon-Martre H, et al. Therapeutic drug monitoring of amprenavir and correlation with antiviral efficacy in highly experienced patients. [abstract. 5.7]. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, the Netherlands, 2-4 April 2001.
16. Baxter JD, Merigan TC, Wentworth DN, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002; 16:1131-1138.
17. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 16:2311-2315.
18. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5:352-359.
19. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services (DHHS) Panel on clinical Practices for treatment of HIV infection. Washington, DC: US Goverment Printing Office, 2004.
20. Hirsh MS et al: Antiretroviral drug resistance testing in adults infected with HIV-1: 2003 recommendation of an International AIDS Society-USA Panel. Clin Infect Dis, 2003; 37:113-28.
21. Little SJ Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther. 2000 5:33-40
22. Tamalet C, Fantini J, Tourres C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS. 2003;17:2383-8.
23. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-401.
24. Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retroviruses. 2004;20:1-9.
25. Scott P, Arnold E, Evans B, Pozniak A, Moyle G, Shahmenesh M, White D, Shirley J, Cane P, Pillay D. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother. 2004;53:469-73.
26. Zaccarelli M, Perno CF, Forbici F, et al. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir Ther. 2003;8:51-6.
27. Yahi N, Fantini J, Tourres C, Tivoli N, Koch N, Tamalet C. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J Infect Dis. 2001;183:1311-7.
28. Kuiken C, Korber B, Shafer RW. HIV sequence databases. AIDS Rev. 2003;5:52-61.
29. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther. 2004;9:631-3.
30. Brun-Vezinet F, Costagliola D, Khaled MA, et al.. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004;9:465-78.

Parole Chiave

HIV-1; FARMACI ANTIRETROVIRALI; RESISTENZA PRIMARIA; RESISTENZA GENOTIPICA; FALLIMENTO TERAPEUTICO; DATABASE; DOSAGGIO PLASMATICO DEI FARMACI; HIV-1 DNA